3DSNA |
|
Vaxjo ID |
402 |
|
Vaccine Adjuvant Name |
3DSNA |
|
Alternative Names |
3DSNA may be referred to as a supramolecular nanoadjuvant. |
|
Adjuvant VO ID |
VO_0005517
|
|
Description |
3DSNA is a peptide-based supramolecular nanoadjuvant that self-assembles into nanofibers and is designed to enhance the immune response to co-delivered antigens, such as tumor-associated proteins. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
we synthesized an NF-κB-activating supramolecular nanoadjuvant (3DSNA) that is prepared by pH-triggering self-assembly of a positively charged D-configurational peptide derivative. The immunostimulatory activity of 3DNSA was explored in vitro and in vivo. |
|
Structure |
3DSNA consists of peptide derivatives that self-assemble into nanofibers, with specific amino acid configurations that enhance their adjuvant properties. |
|
Preparation |
3DSNA is prepared by adjusting the pH of a peptide solution to induce self-assembly into nanofibers. |
|
Dosage |
In the study, 3DSNA was used in combination with antigens at a dosage of 100 ug per formulation. |
|
Function |
Type: particulate antigen delivery system vaccine adjuvant. Target Receptor: Toll-like receptor 9 (TLR9). Induces Th1-biased immune profile. 3DSNA promotes ingestion and cross-presentation of OVA, upregulation of costimulatory factors (CD80 and CD86) and secretion of proinflammatory cytokines (IL-6 and IL-12) by dendritic cells (DCs), accompanied by activation of the innate immune response (NF-κB signaling), resulting in long-term antigen-specific memory and effector CD8+ T cells response. When compared with conventional aluminum hydroxide adjuvant and the corresponding L-configurational supramolecular nanoadjuvant (3LSNA), 3DSNA-adjuvanted OVA (3DSNA+OVA) significantly prevents oncogenesis in naïve mice with a complete response rate of 60 %, restrains the tumor growth and prolongs the survival of melanoma-bearing mice. Conclusion: These findings demonstrate that 3DSNA is a promising neo-adjuvant that enables various vaccines to be therapeutic for many important diseases including cancer. |
|
Safety |
The article indicates that 3DSNA has good biocompatibility and safety profiles, as it is designed to minimize adverse effects while effectively enhancing immune responses. |
| References |
Xu et al., 2019: Xu Y, Wang Y, Yang Q, Liu Z, Xiao Z, Le Z, Yang Z, Yang C. A versatile supramolecular nanoadjuvant that activates NF-κB for cancer immunotherapy. Theranostics. 2019; 9(11); 3388-3397. [PubMed: 31244959].
|
